Rae S M Yeung

List of Publications by Year
in descending order

128 papers	5,565 citations	70961 41 h-index	91712 69 g-index
137 all docs	137 docs citations	137 times ranked	5991 citing authors

#	Article	IF	Citations
1	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€2 and Hyperinflammation in Pediatric COVIDâ€19: Version 1. Arthritis and Rheumatology, 2020, 72, 1791-1805.	2.9	323
2	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€2 and Hyperinflammation in Pediatric COVIDâ€19: Version 2. Arthritis and Rheumatology, 2021, 73, e13-e29.	2.9	314
3	Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nature Genetics, 2011, 43, 1241-1246.	9.4	297
4	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2015, 74, 1854-1860.	0.5	192
5	Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease. Nature Communications, 2017, 8, 14816.	5.8	176
6	TNF-Î± Is Necessary for Induction of Coronary Artery Inflammation and Aneurysm Formation in an Animal Model of Kawasaki Disease. Journal of Immunology, 2006, 176, 6294-6301.	0.4	156
7	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€2 and Hyperinflammation in Pediatric COVIDâ€19: Version 3. Arthritis and Rheumatology, 2022, 74, .	2.9	146
8	HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	3.3	139
9	Infections and Kawasaki Disease: Implications for Coronary Artery Outcome. Pediatrics, 2005, 116, e760-e766.	1.0	127
10	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Annals of the Rheumatic Diseases, 2017, 76, 906-913.	0.5	123
11	Asking the experts: Exploring the selfâ€management needs of adolescents with arthritis. Arthritis and Rheumatism, 2008, 59, 65-72.	6.7	122
12	Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. Journal of Pediatrics, 2002, 140, 450-455.	0.9	119
13	Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. Arthritis and Rheumatology, 2016, 68, 2514-2526.	2.9	103
14	Inositol-Triphosphate 3-Kinase C Mediates Inflammasome Activation and Treatment Response in Kawasaki Disease. Journal of Immunology, 2016, 197, 3481-3489.	0.4	99
15	Arthritis presenting during the acute phase of Kawasaki disease. Journal of Pediatrics, 2006, 148, 800-805.	0.9	93
16	Kawasaki disease: update on pathogenesis. Current Opinion in Rheumatology, 2010, 22, 551-560.	2.0	90
17	Kawasaki Disease at the Extremes of the Age Spectrum. Pediatrics, 2009, 124, e410-e415.	1.0	87
18	A combined immunodeficiency with severe infections, inflammation, and allergy caused by ARPC1B deficiency. Journal of Allergy and Clinical Immunology, 2019, 143, 2296-2299.	1.5	87

#	Article	IF	Citations
19	Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care and Research, 2010, 62, 527-536.	1.5	86
20	Macrophage Activation Syndrome in the Acute Phase of Kawasaki Disease. Journal of Pediatric Hematology/Oncology, 2010, 32, 527-531.	0.3	77
21	Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease. International Immunology, 2003, 15, 79-89.	1.8	75
22	Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis and Rheumatism, 2008, 58, 854-863.	6.7	74
23	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nature Communications, 2016, 7, 12460.	5.8	73
24	Complete and incomplete Kawasaki disease: two sides of the same coin. European Journal of Pediatrics, 2012, 171, 657-662.	1.3	72
25	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2016, 75, 1092-1098.	0.5	72
26	The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 3463-3475.	2.9	69
27	Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: Results of a Canadian multicenter, prospective inception cohort study. Arthritis and Rheumatism, 2009, 61, 1077-1086.	6.7	68
28	Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006. Pediatrics International, 2010, 52, 699-706.	0.2	64
29	Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock. European Journal of Immunology, 1996, 26, 1074-1082.	1.6	58
30	Comparison of Factors Associated With Coronary Artery Dilation Only Versus Coronary Artery Aneurysms in Patients With Kawasaki Disease. American Journal of Cardiology, 2009, 104, 1743-1747.	0.7	58
31	Epidemiology and Management of Kawasaki Disease. Drugs, 2012, 72, 1029-1038.	4.9	56
32	Early Outcomes in Children With Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1470-1479.	2.9	56
33	Childhood Takayasu arteritis: disease course and response to therapy. Arthritis Research and Therapy, 2017, 19, 255.	1.6	54
34	Brief Report: The Genetic Profile of Rheumatoid Factorâ€“Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 957-962.	2.9	53
35	Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution. PLoS ONE, 2018, 13, e0191087.	1.1	53
36	Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature Reviews Rheumatology, 2021, 17, 257-269.	3.5	52

#	Article	IF	Citations
37	MIS-C: early lessons from immune profiling. Nature Reviews Rheumatology, 2021, 17, 75-76.	3.5	51
38	Healthâ€Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. Arthritis Care and Research, 2018, 70, 134-144.	1.5	50
39	Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clinical and Experimental Immunology, 2009, 157, 300-309.	1.1	49
40	Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis and Rheumatism, 2009, 60, 2131-2141.	6.7	48
41	Assessment of sample collection and storage methods for multicenter immunologic research in children. Journal of Immunological Methods, 2008, 339, 82-89.	0.6	47
42	Genetic Variation in the SLC8A1 Calcium Signaling Pathway Is Associated With Susceptibility to Kawasaki Disease and Coronary Artery Abnormalities. Circulation: Cardiovascular Genetics, 2016, 9, 559-568.	5.1	45
43	Generation of Humanized Mice Susceptible to Peptide-Induced Inflammatory Heart Disease. Circulation, 1999, 99, 1885-1891.	1.6	43
44	Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease. Frontiers in Immunology, 2019, 10, 185.	2.2	43
45	Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis. Arthritis and Rheumatology, 2019, 71, 1747-1755.	2.9	41
46	IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukinâ€1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1319-1330.	2.9	40
47	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatric Rheumatology, 2017, 15, 68.	0.9	39
48	Pathogenesis and treatment of Kawasaki??s disease. Current Opinion in Rheumatology, 2005, 17, 617-623.	2.0	38
49	Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment. International Journal of Cardiology, 2017, 236, 157-161.	0.8	38
50	Presentation and Disease Course of Childhoodâ€Onset Versus Adultâ€Onset Takayasu Arteritis. Arthritis and Rheumatology, 2019, 71, 315-323.	2.9	38
51	The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clinical and Experimental Immunology, 2011, 164, 193-201.	1.1	36
52	Patterns of joint involvement in juvenile idiopathic arthritis and prediction of disease course: A prospective study with multilayer non-negative matrix factorization. PLoS Medicine, 2019, 16, e1002750.	3.9	36
53	Coronary artery dilation after Kawasaki disease for children within the normal range. International Journal of Cardiology, 2009, 136, 27-32.	0.8	35
54	Longterm outcomes in patients with giant aneurysms secondary to Kawasaki disease. Journal of Rheumatology, 2005, 32, 928-34.	1.0	35

#	Article	IF	Citations
55	Echocardiographic and electrocardiographic trends in children with acute Kawasaki disease. Canadian Journal of Cardiology, 2008, 24, 776-780.	0.8	34
56	Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression. International Journal of Cardiology, 2012, 154, 9-13.	0.8	33
57	Presence of IFN-Î³ Does Not Indicate Its Necessity for Induction of Coronary Arteritis in an Animal Model of Kawasaki Disease. Journal of Immunology, 2004, 173, 3492-3503.	0.4	30
58	Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. Pain, 2018, 159, 57-66.	2.0	29
59	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. Journal of Rheumatology, 2021, 48, 555-566.	1.0	27
60	Intravenous immunoglobulin preparation type: Association with outcomes for patients with acute Kawasaki disease. Pediatric Allergy and Immunology, 2010, 21, 515-521.	1.1	26
61	Atorvastatin Safety in Kawasaki Disease Patients With Coronary Artery Aneurysms. Pediatric Cardiology, 2014, 35, 89-92.	0.6	26
62	Prospective Determination of the Incidence and Risk Factors of Newâ€Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort. Arthritis Care and Research, 2019, 71, 1436-1443.	1.5	26
63	Corticosteroid treatment of refractory Kawasaki disease. Journal of Rheumatology, 2006, 33, 803-9.	1.0	25
64	Imaging of systemic vasculitis in childhood. Pediatric Radiology, 2015, 45, 1110-1125.	1.1	24
65	Pediatric inflammatory multisystem syndrome temporally associated with COVID-19: a spectrum of diseases with many names. Cmaj, 2020, 192, E1093-E1096.	0.9	24
66	Rate, associated factors and outcomes of recurrence of Kawasaki disease in Ontario, Canada. Pediatrics International, 2012, 54, 383-387.	0.2	22
67	The etiology of Kawasaki disease: a superantigen-mediated process. Progress in Pediatric Cardiology, 2004, 19, 115-122.	0.2	20
68	Is multisystem inflammatory syndrome in children on the Kawasaki syndrome spectrum?. Journal of Clinical Investigation, 2020, 130, 5681-5684.	3.9	20
69	Elastolytic Matrix Metalloproteinases and Coronary Outcome in Children with Kawasaki Disease. Pediatric Research, 2007, 61, 710-715.	1.1	19
70	Inhibition of Transforming Growth Factor Î² Worsens Elastin Degradation in a Murine Model of Kawasaki Disease. American Journal of Pathology, 2011, 178, 1210-1220.	1.9	19
71	Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1043-1051.	2.2	19
72	Parental Anxiety Associated With Kawasaki Disease in Previously Healthy Children. Journal of Pediatric Health Care, 2010, 24, 250-257.	0.6	18

#	Article	IF	Citations
73	Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist. Pediatric Rheumatology, 2019, 17, 31.	0.9	17
74	Factors Associated with a Longer Time to Access Pediatric Rheumatologists in Canadian Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2010, 37, 2415-2421.	1.0	16
75	Description of Active Joint Count Trajectories in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 2466-2473.	1.0	16
76	Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease. Journal of Pediatrics, 2016, 179, 124-130.e1.	0.9	16
77	Treatment-associated hemolysis in Kawasaki disease: association with blood-group antibody titers in IVIG products. Blood Advances, 2020, 4, 3416-3426.	2.5	16
78	Arterial dissection in childhood Takayasu Arteritis: not as rare as thought. Pediatric Rheumatology, 2016, 14, 56.	0.9	13
79	Enhancing translational research in paediatric rheumatology through standardization. Nature Reviews Rheumatology, 2016, 12, 684-690.	3.5	13
80	Factors Associated With Low Moderate-to-Vigorous Physical Activity Levels in Pediatric Patients With Kawasaki Disease. Clinical Pediatrics, 2012, 51, 828-834.	0.4	12
81	Outcome of kidney transplantation in pediatric patients with ANCA-associated glomerulonephritis: a single-center experience. Pediatric Nephrology, 2017, 32, 2343-2350.	0.9	12
82	A Clinically and Biologically Based Subclassification of the Idiopathic Inflammatory Myopathies Using Machine Learning. ACR Open Rheumatology, 2020, 2, 158-166.	0.9	12
83	Phase <scp>IIa</scp> Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis. Arthritis and Rheumatology, 2022, 74, 124-133.	2.9	12
84	The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. Journal of Rheumatology, 2004, 31, 844-6.	1.0	12
85	Phenotype and coronary outcome in Kawasaki's disease. Lancet, The, 2007, 369, 85-87.	6.3	11
86	Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. Rheumatology, 2020, 59, 2402-2411.	0.9	11
87	Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease. Current Opinion in Rheumatology, 2017, 29, 547-552.	2.0	10
88	Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review. Pediatric Rheumatology, 2019, 17, 20.	0.9	10
89	Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis â€“ Two Ends of the Same Spectrum. Frontiers in Pediatrics, 2021, 9, 665815.	0.9	10
90	Malignancy incidence in 5294 patients with juvenile arthritis. RMD Open, 2016, 2, e000212.	1.8	9

#	Article	IF	Citations
91	Associations of clinical and inflammatory biomarker clusters with juvenile idiopathic arthritis categories. Rheumatology, 2020, 59, 1066-1075.	0.9	9
92	Lessons learned from an animal model of Kawasaki disease. Clinical and Experimental Rheumatology, 2007, 25, S69-71.	0.4	9
93	TNF and IL-1 Targeted Treatment in Kawasaki Disease. Current Treatment Options in Rheumatology, 2016, 2, 283-295.	0.6	8
94	Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. Pediatric Rheumatology, 2018, 16, 17.	0.9	8
95	Increased Arterial Stiffness Adversely Affects Left Ventricular Mechanics in Patients With Pediatric Takayasu Arteritis From a Toronto Cohort. Journal of Clinical Rheumatology, 2019, 25, 171-175.	0.5	8
96	Treatment of rituximab-associated chronic CNS enterovirus using IVIg and fluoxetine. Neurology, 2019, 92, 916-918.	1.5	8
97	Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 975-984.	0.7	8
98	A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. Arthritis Research and Therapy, 2020, 22, 53.	1.6	8
99	Clinical and psychosocial stress factors are associated with decline in physical activity over time in children with juvenile idiopathic arthritis. Pediatric Rheumatology, 2021, 19, 97.	0.9	8
100	Gene Expression Deconvolution for Uncovering Molecular Signatures in Response to Therapy in Juvenile Idiopathic Arthritis. PLoS ONE, 2016, 11, e0156055.	1.1	8
101	Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. Pediatric Rheumatology, 2022, 20, 25.	0.9	8
102	Stability of 40 cytokines/chemokines in chronically ill patients under different storage conditions. Cytokine, 2020, 130, 155057.	1.4	7
103	Kawasaki disease and scald injuries: a possible association. Canadian Journal of Cardiology, 2004, 20, 1147-9.	0.8	7
104	A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort. Arthritis and Rheumatology, 2022, 74, 1409-1419.	2.9	7
105	Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Rheumatology and Therapy, 2021, 8, 1303-1322.	1.1	6
106	Kawasaki Disease-Associated Cytokine Storm Syndrome. , 2019, , 393-406.		6
107	An Update on Childhood-Onset Takayasu Arteritis. Frontiers in Pediatrics, 2022, 10, 872313.	0.9	6
108	The immune-stimulation capacity of liposome-treated red blood cells. Journal of Liposome Research, 2018, 28, 173-181.	1.5	5

#	Article	IF	Citations
109	A Toddler Presenting with Pulmonary Renal Syndrome. Case Reports in Nephrology and Dialysis, 2017, 7, 73-80.	0.3	4
110	Evaluation of the functional properties of cryopreserved buffy coatâ€“derived monocytes for monocyte monolayer assay. Transfusion, 2018, 58, 2027-2035.	0.8	4
111	Genomic Health Literacy Interventions in Pediatrics: Scoping Review. Journal of Medical Internet Research, 2021, 23, e26684.	2.1	4
112	Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. Rheumatology, 2023, 62, SI170-SI180.	0.9	4
113	Gene Expression Profiles of Treatment Response and <scp>Nonâ€Response</scp> in Children With Juvenile Dermatomyositis. ACR Open Rheumatology, 2022, 4, 671-681.	0.9	4
114	Costs of <scp>Hospitalâ€Associated</scp> Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System. Arthritis Care and Research, 2022, 74, 1585-1592.	1.5	3
115	The promise of machine learning to inform the management of juvenile idiopathic arthritis. Expert Review of Clinical Immunology, 2021, 17, 1-3.	1.3	3
116	Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. Patient, 2022, 15, 599-609.	1.1	3
117	The Long-term Cardiac and Noncardiac Prognosis of Kawasaki Disease: A Systematic Review. Pediatrics, 2022, 149, .	1.0	2
118	Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis. Rheumatology and Therapy, 2022, 9, 721-734.	1.1	2
119	320.â€ƒPEDIATRIC OPEN-LABEL CLINICAL STUDY OF RITUXIMAB FOR THE TREATMENT OF GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. Rheumatology, 2019, 58, .	0.9	1
120	Update on Pathogenesis: Lessons Learned from Animal Models of Disease. , 2017, , 45-51.		1
121	Wide variation in glucocorticoid dosing in paediatric ANCA-associated vasculitis with renal disease: a paediatric vasculitis initiative study. Clinical and Experimental Rheumatology, 2022, , .	0.4	1
122	A159: The Autoimmune Genetic Architecture of Childhood Onset Rheumatoid Arthritis. Arthritis and Rheumatology, 2014, 66, S205-S206.	2.9	0
123	THU0525â€…DEVELOPMENT OF A PREDICTIVE TOOL FOR RESPONSE TO ANTI-TNF-ALPHA THERAPY IN JIA USING GENE EXPRESSION PROFILES IN PERIPHERAL DERIVED MONONUCLEAR CELLS. , 2019, , .		0
124	Reply. Arthritis and Rheumatology, 2019, 71, 836-838.	2.9	0
125	Soluble Low-density Lipoprotein Receptor-related Protein 1 in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 760-766.	1.0	0
126	Reply. Arthritis and Rheumatology, 2021, 73, 1342-1343.	2.9	0

#	Article	IF	Citations
127	Biologic medicine inclusion in 138 national essential medicines lists. Pediatric Rheumatology, 2021, 19, 140.	0.9	0
128	Paediatric-to-adult transition experience in vasculitis: report of a model of care and outcomes.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0